Clinical Trials Logo

Clinical Trial Summary

Bladder cancer is a common malignant tumor of the urinary system, radical resection plus urinary diversion is the first choice of treatment for muscle invasive bladder cancer. Urinary diversion of surgical options related to patient' survival and quality of life. In 1988, Hautmann firstly reported an orthotopic urinary diversion method: Hautmann neobladder. As the urine can be controlled from the original urethra, the patient's quality of life has been greatly improved, so the new bladder surgery gradually accepted and welcomed by urologists and patients. However, in order to achieve low-pressure and large-volume storage capacity of the urine reservoir, the 40-70cm long interception of terminal ileum need to be detubularized. Only after split, folded, re-stitched and a series of treatment, the intestinal can be used. Such complicated procedures make so many urologists give it up. In addition, the interception of the long ileum may lead to reduced absorption of vitamin B12 which caused anemia, metabolic acidosis, intestinal dysfunction. Not only that, as time goes by, this kind of neobladder will be unlimited expansion and resulting in a serious increase in residual urine volume, hydronephrosis, or even the occurrence of neobladder spontaneous rupture. In 2000, professor Chunxiao Liu invented "detaenial sigmoid neobladder", this surgical method overset the traditional intestinal detubularization approach, which detached the serosal layer with smooth muscle from the bowel without split it. This kind of neobladder is easier to construct and have less impact on intestinal function. So far, it has been implemented for more than 600 cases in Zhujiang hospital, the age of patients range from 9 months (bladder rhabdomyosarcoma) to 84 years old. So far as now, no multicenter prospective clinical study on orthotopic urinary diversion has been performed worldwide, neither the head-to-head studies on detaenial sigmoid neobladder and ileal neobladder. Our project is going to perform a multicenter randomized controlled trial for these two neobladder methods and look forward to assess the safety and efficacy of these two procedures which provide an objective basis for the patients undergoing orthotopic urinary diversion in the future.


Clinical Trial Description

Surgical technique for Hautmann ileal neobladder: A 70-cm portion of terminal ileum is selected and incised on the antimesenteric border. The ileum is arranged into an M or W configuration with the four limbs sutured to one another. After a buttonhole of ileum is removed on an antimesenteric portion of the ileum, the urethral anastomosis is performed. The ureteral anastomoses are performed using a Le Duc technique or direct implantation, are stented, and the reservoir is then closed in a side-to-side manner. As an alternative, the two ends of the W may be left slightly longer as a short chimney on either side for implantation of the ureters. Surgical technique for detaenial sigmoid neobladder: After radical cystectomy, the sigmoid was brought out from a midline incision in the lower abdomen and a 15 to 25 cm segment was isolated. Intestinal continuity was restored using a circular stapler. Omental and free taeniae, and the serosal layer were incised deeply as far as the submucosal layer until the plane between smooth muscle and the submucosal layer could be identified clearly by scalpel dissection. The serosal layer with smooth muscle was then detached from the submucosal layer and removed continuously without difficulty. During this time, the operator could insert the finger in the sigmoid lumen and lift the sigmoid wall up for accurate dissection. Only the mucosal and submucosal layers were preserved. Approximately 2 to 3 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The detaenial sigmoid was irrigated repeatedly by dilute iodine solution to eliminate impurities. Its capacity for enlargement and leak tightness were assessed at the end by filling with 300 to 400 ml iodine solution. Residual taeniae were identified and incised during this filling phase. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel with 4-zero poly glactin at the two ends of sigmoid. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. Each stent was passed through the sigmoid wall and exteriorized. The two ends of the sigmoid were closed by 2-zero polyglactin with the embedded seromuscular layer. The central portion of the sigmoid was incised and a 22Fr 3-way catheter was inserted in neobladder. The neobladder was anastomosed to the urethra with 2-zero polyglactin. Followup: Each patient was evaluated at 3-month intervals for 1 year, at 6-month intervals for 2 to 5 years. Renal ultrasound, biochemical examination and urine culture were done every 3 to 6 months. Pelvic computerized tomography and retro-cystogram were performed 6 months postoperatively and annually thereafter. Urodynamic investigation and cystoscopic examination were done annually. Postoperative complications were classified as early (90 days or less) and late (greater than 90 days). Early and late complications were subdivided into those related and not related to the neobladder. Complication grade was classified according to the Clavien-Dindo system. Major complications were defined as grade III or higher. Daytime and nighttime continence levels were recorded postoperatively at patient interview. Continence was defined as complete if the patient was dry without a pad, satisfactory if no more than 1 pad was required and poor if the patient used more than 1 pad during the day or night. End points: The primary end point was change in renal function from baseline to 3 years. Secondary end points included changes in renal function from baseline to 6, 12 and 24 months, reduction in eGFR 10 ml/minute/1.73 m2 or greater, early (less than 90 days) and late (90 days to 3 years) complications, urinary tract infection that was symptomatic or was treated, any surgical re-intervention or urinary diversion related surgical re-intervention defined as an open or endoscopic procedure under anesthesia, cancer recurrence and overall survival. Renal function was assessed using the CKD-EPI equation. Complications were analyzed and graded by a blinded adjudicator using the modified Clavien complication grading system. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03108196
Study type Interventional
Source Zhujiang Hospital
Contact Abai Xu, doctor
Phone +86 18665626790
Email lc96xab@163.com
Status Recruiting
Phase N/A
Start date May 2, 2018
Completion date September 30, 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A